NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-eluting Stent Trial
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3235 participants.
Also called NCT01303640
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 3,235 participants
- Sponsor
- Registry
-
NCT01303640
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT01303640. Randomized; no masking; primary purpose treatment. Start 2011-05 (registry gives no type); primary completion 2015-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-eluting Stent Trial
- Acronym
- NEXT
- Condition
- Coronary Artery Disease
- Intervention (Device)
- Biolimus-eluting stent
- Intervention (Device)
- Everolimus-eluting stent
- Lead sponsor
- Takeshi Morimoto
Record details
- Record id
cardio:ct-nct01303640- Content hash
b1b855eaaa66cd796adc7b00bf39d36ca38878d690fab14f0b3d72ae74f7c6d5